In dealtalk, Novartis plans to exit an eight-year-old vaccines joint venture with India's Panacea Biotec and intends to go it alone.
Dealtalk suggests that the collaboration, which focused on the development and sale of paediatric vaccines for the Indian market, will soon be dissolved.
The joint venture was set up in 2004 between Panacea and Chiron, which was acquired by Novartis for $7.5bn back in 2008 as a bolt-on vaccines unit. It sells a range of vaccines including shots against polio, hepatitis B, anthrax and dengue fever, as well as pentavalent vaccines used in childhood immunisation programmes.
The dealtalk suggests that Panacea will have to find another marketing partner for its vaccines business, which has been struggling in the wake of a World Health Organization (WHO) decision to remove it from the prequalified list of pentavalent vaccine suppliers in 2011.
Meanwhile, the company has also fallen foul of regulatory authorities in India, which seized more than 15,000 vials of pentavalent vaccine earlier this year after an investigation suggested that expiry dates on their labels had been falsified.
The company secured a 345 million polio vaccine order from the Indian government last December worth around $27m, and there have also been signs that Panacea's non-vaccine business has been picking up of late, according to dealtalk.
It also forged two new collaborations for generic pharmaceutical products signed towards the end of last year with UCB subsidiary Kremers Urban Pharmaceuticals and Osmotica Pharmaceutical, according to dealtalk.
Report: Partnering Deals and Alliances with Novartis
Report: Trends in Therapeutic Partnering
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity